Blueprint Meds: durable clinical benefits for Gavreto in thyroid cancer

 

Blueprint Medicines (BPMC -0.4%) has announced results from the ongoing ARROW (Phase 1/2) trial for GAVRETO (pralsetinib) in patients with advanced RET-mutant medullary thyroid cancer (MTC). The data were presented at the European Society for Medical Oncology Virtual Congress.

In 53 previously treated patients (with cabozantinib or vandetanib), GAVRETO demonstrated overall response rate (ORR) was 60%, and the disease control rate (DCR) of 96%

Median duration of response was not reached, with 94% of responders remaining on treatment. Also median progression-free survival (PFS) was not reached in patients previously treated with cabozantinib or vandetanib.

In 19 systemic treatment-naïve patients who were ineligible for standard therapy, confirmed ORR of 74%, and DCR of 100% was observed. Median DOR and PFS was not reached.

Five of six patients whose tumors had a RET V804M or V804L gatekeeper mutation achieved a clinical response.

GAVRETO was well-tolerated, and overall, treatment-related adverse events were primarily mild to moderate. Investigator-reported serious/servere adverse events were hypertension, neutropenia, anemia and decreased neutrophil count. 4% of patients discontinued GAVRETO due to treatment-related AEs.

GAVRETO (pralsetinib) is a once-daily oral targeted therapy approved by the FDA for the treatment of adults with metastatic RET fusion-positive non-small cell lung cancer.

https://seekingalpha.com/news/3615768-blueprint-medicines-says-durable-clinical-benefits-observed-for-gavreto-in-thyroid-cancer